Skip to main content Help with accessibility Skip to main navigation

Upadacitinib

Red

Brand:

Rinvoq

Nice TA:

861

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system

Background

1.1 Upadacitinib is recommended as an option for treating active non- radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if:

tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and

the company provides upadacitinib according to the commercial arrangement.

1.2 Assess response to upadacitinib after 16 weeks of treatment. Continue treatment only if there is clear evidence of response, defined as a reduction in:

the Bath Ankylosing

Spondylitis Disease Activity Index (BASDAI) score to 50% of the pretreatment value or by 2 or more units and

the spinal pain visual analogue scale (VAS) by 2 cm or more.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 17 - Mar - 2023